Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Melanoma combination therapies ward off tumor resistance.

Literature DB >> 23929325

Melanoma combination therapies ward off tumor resistance.

Ken Garber.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2013 PMID： 23929325 DOI： 10.1038/nbt0813-666b

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

4 in total

1. Cautious optimism surrounds early clinical data for PD-1 blocker.

Authors: Cormac Sheridan
Journal: Nat Biotechnol Date: 2012-08 Impact factor: 54.908

2. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors: Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal: N Engl J Med Date: 2012-09-29 Impact factor: 91.245

3. Nivolumab plus ipilimumab in advanced melanoma.

Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

4. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors: Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal: Nature Date: 2012-07-26 Impact factor: 49.962

4 in total

3 in total

Melanoma combination therapies ward off tumor resistance.

1. Cautious optimism surrounds early clinical data for PD-1 blocker.

2. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

3. Nivolumab plus ipilimumab in advanced melanoma.

4. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

1. A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis.

2. "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.

Review 3. Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.